Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.67 -0.67 (-1.25%)

Streaming Delayed Price Updated: 12:22 PM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

31 32 33 34 35 36 37 38 Next >

Data for Genentech’s Evrysdi (risdiplam) Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)

July 28, 2021

From Genentech

Via Business Wire

OTC Markets Hits Major Milestones in Mid-Year Along With Big Volume and Gaining Securities ↗

July 28, 2021

Photo by Kyrie Kim on Unsplash In a similar vein to 2020, the market’s volatility to start 2021 gave way to less volatility in the second quarter, and even less volatility...

Via Benzinga

Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings ↗

July 27, 2021

Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49...

Via Benzinga

Joblessness Surprise ↗

July 22, 2021

Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices.

Via Talk Markets

Roche Puts Alzheimer's Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters ↗

July 22, 2021

Roche Holding AG (OTC: RHHBY) is reportedly talking to the FDA about its Alzheimer’s disease drug candidate, gantenerumab. CEO Severin Schwan declined...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021 ↗

July 22, 2021

Upgrades According to Stephens & Co., the prior rating for World Acceptance Corp (NASDAQ:...

Via Benzinga

Rebound In COVID-19 Tests Lift Roche's Half-Year Sales, Oncology Still Hit By Biosimilars, Pandemic ↗

July 22, 2021

Roche Holding AG's (OTC: RHHBY) 1H 2021 sales increased by 8% Y/Y at constant exchange rates (CER) to CHF 30.7 billion as peak demand for COVID-19 tests helped...

Via Benzinga

Panic Attack ↗

July 21, 2021

The H1 rise in US markets was based on hope for an end to lockdowns.

Via Talk Markets

Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression ↗

July 21, 2021

Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced updated data from the ongoing Phase 1/2 trial of SPK-8011 gene therapy in...

Via Benzinga

AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes ↗

July 21, 2021

The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with azacitidine for the potential treatment of adult patients with...

Via Benzinga

FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes

July 21, 2021

From Genentech

Via Business Wire

The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay ↗

July 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,...

Via Benzinga

Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A ↗

July 19, 2021

According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A...

Via Benzinga

New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A

July 19, 2021

From Genentech

Via Business Wire

Biogen Stock And The Aduhelm Drama: Will It Really Treat Alzheimer's? ↗

July 15, 2021

The fate of Biogen stock is now intricately tied to the success — or failure — of its controversial Alzheimer's treatment, Aduhelm.

Via Investor's Business Daily

5 Stocks to Own for the Surge in Coronavirus Variants ↗

July 14, 2021

Despite easing restrictions, COVID is going to be around a lot longer than many think.

Via The Motley Fool

Yellow Card ↗

July 12, 2021

The price of oil fell about 1% today.

Via Talk Markets

Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159 ↗

July 12, 2021

Celldex Therapeutics Inc (NASDAQ: CLDX) got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021 ↗

July 08, 2021

Upgrades For FB Financial Corp (NYSE:

Via Benzinga

WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients ↗

July 07, 2021

The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients...

Via Benzinga

Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today ↗

July 06, 2021

Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ:...

Via Benzinga

New Month And Half Year ↗

July 01, 2021

Welcome to H2. In theory, if markets did well in H1 they tend to close the year up.

Via Talk Markets

End Of June ↗

June 30, 2021

Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made.

Via Talk Markets

Topics Initial Public Offering

Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients ↗

June 30, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-...

Via Benzinga

Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact ↗

June 29, 2021

Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it...

Via Benzinga

Topics Intellectual Property

Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer ↗

June 28, 2021

Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (...

Via Benzinga

Roche's Enspryng Wins European Approval For Spinal Cord, Optic Nerve Inflammation Disorder ↗

June 28, 2021

The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder...

Via Benzinga

FDA Gives Emergency Use Nod For Roche's Arthritis Drug Against Severe COVID-19 ↗

June 25, 2021

The

Via Benzinga

The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs ↗

June 25, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children

June 24, 2021

From Genentech

Via Business Wire

< Previous 1 2

...

31 32 33 34 35 36 37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.